Shareholders meeting

Corporate Office: Solara Active Pharma Sciences Limited TICEL Bio Park, 6th Floor, Module No. 601, 602, 603, Phase II – CSIR Road, Taramani, Chennai, Tamil Nadu – 600113. Tel: +91 44 4344 6700 Fax: +91 44 47406190 E-mail: investors@solara.co.in Website: www.solara.co.in Date: August 25, 2026 The BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra-Kurla Complex, Dalal Street, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 541540, 890202 Symbol: SOLARA, SOLARAPP1 Dear Sir / Madam, Subject: Notice of Ninth Annual General Meeting and Annual Report for the financial year 2025-26 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Notice convening Ninth Annual General Meeting (AGM) along with the Annual Report for the financial year 2025-26 which will be circulated to the shareholders through electronic mode. The Ninth AGM is scheduled to be held on Friday, September 18, 2026, at 10.30 A.M (IST) through Video Conference (VC) / Other Audio-Visual Means (OAVM), in accordance with the Circulars issued by Ministry of Corporate Affairs (MCA), SEBI and applicable provisions of the Companies Act, 2013 and the Rules made thereunder. The Notice along with the Annual Report for the financial year 2025-26 made available on the Company's website at https://solara.co.in/investor-relations/annual-reports/#annual The schedule of AGM is as set out below: Particulars Details Date and Time of AGM Friday, September 18, 2026 at 10.30 AM (IST). Eligible to vote – Cut-off date Friday, September 11, 2026 Remote e-voting start date and time Tuesday, September 15, 2026; 9.00 AM (IST) Remote e-voting end date and time Thursday, September 17, 2026; 5.00 PM (IST) Website of CDSL for remote e-voting and https://www.evotingindia.com/ or participation in the AGM https://eservices.nsdl.com Kindly take the above information on records. Thanking You, Yours Faithfully, For Solara Active Pharma Sciences Limited Pooja Jaya Kumar Company Secretary & Compliance Officer ICSI Membership No.: A57415 Solara Active Pharma Sciences Limited - CIN: L24230MH2017PLC291636 Registered Office: Cyber One, Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703; Tel: +91-22-20870033 Notice Solara Active Pharma Sciences Limited CIN: L24230MH2017PLC291636 Registered Office: Cyber One’, Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703; Tel: +91-22-20870033 Corporate Office: TICEL Bio Park, 6th Floor, Module No. 601, 602, 603, Phase II – CSIR Road, Taramani, Chennai, Tamil Nadu – 600113. Tel: +91 44 4344 6700 E-mail: investors@solara.co.in Website: www.solara.co.in NOTICE NOTICE is hereby given that the Ninth Annual General “RESOLVED THAT pursuant to the provisions Meeting of the Members of the Company will be held on of section 152 of the Companies Act, 2013 and Friday, September 18, 2026, at 10.30 A.M. through rules made thereunder (including any statutory Video Conferencing (“VC”) / Other Audio-Visual Means modification and re-enactment thereof and other (“OAVM”) to transact the following businesses. applicable provisions, if any of the Companies Act, 2013), Mr. Arun Kumar Pillai, (DIN: 00084845) who ORDINARY BUSINESS retires by rotation, be and is hereby re-appointed as a Non-Executive Director of the Company, liable 1. To receive, consider and adopt the Audited to retire by rotation. Standalone Financial Statements of the Company for the financial year ended March 31, 2026, SPECIAL BUSINESS together with the Reports of the Board of Directors and the Auditors thereon, and in this regard, to 4. To ratify the remuneration payable to Cost Auditors consider and if thought fit, to pass the following for the financial year ending March 31, 2027, and in resolution as Ordinary Resolution: this regard, to consider and if thought fit, to pass the following resolution as an Ordinary Resolution: “RESOLVED THAT the Audited Standalone Financial Statement of the Company for the financial year RESOLVED THAT pursuant to the provisions of ended March 31, 2026 and the reports of the Board Section 148(3) and other applicable provisions, of Directors and Auditors thereon, as circulated to if any, of the Companies Act, 2013 read with the the members, be and are hereby considered and Companies (Audit and Auditors) Rules, 2014 adopted.” (including any statutory modification(s) or re- enactment(s) thereof for the time being in force), the 2. To receive, consider and adopt the Audited remuneration of ` 4,75,000/- (Rupees Four Lakhs Consolidated Financial Statements of the Company Seventy-Five Thousand only), plus reimbursement for the financial year ended March 31, 2026, together of out-of-pocket expenses and applicable taxes, with the Report of the Auditors thereon, and in this payable to Mr. K. Suryanarayanan, Practising Cost regard, to consider and if thought fit, to pass the Accountant (Membership No. 24946), who was following resolution as Ordinary Resolution: appointed as the Cost Auditor of the Company “RESOLVED THAT the Audited Consolidated for the financial year ending March 31, 2027, by Financial Statement of the Company for the the Board of Directors of the Company on the financial year ended March 31, 2026 and the report recommendation of the Audit Committee, be and of Auditors thereon, as circulated to the members, is hereby ratified and confirmed. be and are hereby considered and adopted.” RESOLVED FURTHER that any Director or the 3. To appoint Mr. Arun Kumar Pillai (DIN: 00084845), Company Secretary of the Company be and are who retires by rotation and being eligible offers hereby severally authorised to do all such acts, deeds, himself for re-appointment as a Non - Executive matters and things and to execute and deliver all Director, and in this regard, to consider and if such necessary documents for the purpose of giving thought fit, to pass the following resolution as effect to the aforesaid resolution.” Ordinary Resolution: Annual Report 2025-26 239 5. To approve Material Related Party Transactions/ upon between the Company and Strides for an Contracts/ Arrangements with Strides Pharma aggregate amount up to ` 480 crores (Rupees Four Science Limited up to ` 480 crores, and in this Hundred and Eighty Crores), provided that the said regard, to consider and if thought fit, to pass the contract(s)/ arrangement(s)/ transaction(s) shall be following resolution as an Ordinary Resolution: carried out at arm’s length basis and in the ordinary course of business of the Company, from the date “RESOLVED that pursuant to the applicable of this Annual General Meeting (“AGM”) up to the provisions of the Companies Act, 2013 (“the Act”) date of next AGM to be held in the calendar year read with the rules framed thereunder (including 2027, for the purposes as set out in the explanatory any statutory amendment(s) or re-enactment(s) statement annexed hereto. thereof, for the time being in force, if any), and in terms of Regulation 23 of the Securities and RESOLVED FURTHER THAT the Board of Directors Exchange Board of India (Listing Obligations and of the Company (hereinafter referred to as ‘Board’ Disclosure Requirements) Regulations, 2015 which term shall be deemed to include the Audit (hereinafter referred to as the “SEBI Listing Committee of the Board and any duly constituted Regulations”) including any amendments, committee empowered to exercise its powers modification(s) or re-enactment thereof for the including powers conferred under this resolution) time being in force, the Company’s Policy on be and is hereby authorised to do all such acts, Related Party Transactions and basis the approval deeds, matters and things as it may deem fit in and recommendations of the Audit Committee and its absolute discretion, to delegate all or any of the Board of Directors of the Company, approval of its powers conferred under this resolution to any the Members of t [Showing first 8,000 characters — download PDF for full document]